Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High weekly integral dose and larger fraction size increase risk of fatigue and worsening of functional outcomes following radiotherapy for localized prostate cancer.
Joseph N, Cicchetti A, McWilliam A, Webb A, Seibold P, Fiorino C, Cozzarini C, Veldeman L, Bultijnck R, Fonteyne V, Talbot CJ, Symonds PR, Johnson K, Rattay T, Lambrecht M, Haustermans K, De Meerleer G, Elliott RM, Sperk E, Herskind C, Veldwijk M, Avuzzi B, Giandini T, Valdagni R, Azria D, Jacquet MF, Charissoux M, Vega A, Aguado-Barrera ME, Gómez-Caamaño A, Franco P, Garibaldi E, Girelli G, Iotti C, Vavassori V, Chang-Claude J, West CML, Rancati T, Choudhury A. Joseph N, et al. Among authors: de meerleer g. Front Oncol. 2022 Oct 26;12:937934. doi: 10.3389/fonc.2022.937934. eCollection 2022. Front Oncol. 2022. PMID: 36387203 Free PMC article.
Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity.
Fonteyne V, De Neve W, Villeirs G, De Wagter C, De Meerleer G. Fonteyne V, et al. Among authors: de meerleer g, de neve w, de wagter c. Radiother Oncol. 2007 Aug;84(2):156-63. doi: 10.1016/j.radonc.2007.06.013. Epub 2007 Aug 10. Radiother Oncol. 2007. PMID: 17692976
Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion.
Fonteyne V, Villeirs G, Speleers B, De Neve W, De Wagter C, Lumen N, De Meerleer G. Fonteyne V, et al. Among authors: de meerleer g, de neve w, de wagter c. Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):799-807. doi: 10.1016/j.ijrobp.2008.01.040. Epub 2008 Apr 11. Int J Radiat Oncol Biol Phys. 2008. PMID: 18407430
Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial.
Arcangeli S, Strigari L, Soete G, De Meerleer G, Gomellini S, Fonteyne V, Storme G, Arcangeli G. Arcangeli S, et al. Among authors: de meerleer g. Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):39-45. doi: 10.1016/j.ijrobp.2008.04.005. Epub 2008 Jun 4. Int J Radiat Oncol Biol Phys. 2009. PMID: 18538488 Clinical Trial.
202 results